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Summary
Background: Hereditary hemochromatosis (HH) is characterized by excess iron deposition. Two mutations
in the HFE gene are associated with HH. Heterozygous carriers of HFE mutations are at
higher risk of developing type 2 diabetes mellitus (T2DM). The aims of our project were to
identify the frequency of C282Y and H63D mutations in a population from the Ma∏opolska
region of south-eastern Poland, and to search for an association of HFE mutations with
T2DM.
Material/Methods: We included 391 individuals in this study: 222 T2DM patients and 169 controls. Genotypes
were determined by electrophoresis of the DNA digestion products from SnaBI and DpnII,
respectively. Differences in distributions between the groups were then analyzed by the chi-
squared test.
Results: The frequency of wild/C282Y alleles was 98.2%/1.8% in T2DM patients and 96.7%/3.2% in
controls (p=0.19). The frequency of wild/H63D alleles was 85.6%/14.4% and 88.8%/11.2% (p=
0.19), respectively. The distribution of genotypes was not statistically different. However, in
stratified analyses based on age of T2DM onset and gender, we observed a higher prevalence
of wild/H63D and H63D/H63D genotypes among T2DM patients diagnosed at ≥ 49 years of
age, the mean age for the entire group (p=0.018), and among male T2DM individuals
(p=0.005) than in controls.
Conclusion: The frequency of HH-associated mutations in this population from south-eastern Poland is
similar to other Caucasians. We found no evidence for the association of the C282Y mutation
with T2DM. The results do suggest, however, that the H63D mutation may play a role in the
pathogenesis of late onset T2DM and in males in this Polish population.
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BACKGROUND
Type 2 diabetes mellitus (T2DM) is a very common
chronic disease that affects almost 200 million people
worldwide [1]. It is characterized by impaired insulin
secretion and alterations in peripheral insulin action.
The phenotype of T2DM is created by an interaction of
both genetic and environmental factors [2]. Several
genes have been associated with rare monogenic forms
of T2DM [3–6]. These monogenic forms of T2DM are
usually characterized by impaired insulin secretion
[3,4,5], with the exception of insulin receptor mutations
that result in extreme insulin resistance [6]. Recently,
some evidence has been found which appears to indi-
cate the association of calpain 10 and peroxisome prolif-
erator-activated receptor (PPAR)-γ gene polymorphisms
[7,8] with the more common, complex T2DM forms
that are accompanied by both insulin resistance and
abnormalities in insulin secretion. For the most part,
however, the molecular pathophysiology of T2DM is
not yet fully understood. One of the most interesting
candidates for complex forms of T2DM is the HFE
hereditary hemochromatosis (HH) gene [9]. HH is a
frequent, autosomal recessive metabolic disorder char-
acterized by excess iron deposition in various organs.
This gene is related to the major histocompatibility com-
plex class I family [10,11]; its protein binds to the trans-
ferrin receptor, and in so doing reduces its affinity for
iron-loaded transferrin 5 to 10 times [12]. Recently, two
mutations in the HFE gene, one a substitution of tyro-
sine for cysteine at codon 282 (C282Y) and the second a
substitution of histidine with aspartate at codon 63
(H63D), have been linked to HH [9]. The C282Y muta-
tion affects the HFE protein’s structure and function,
disrupting its ability to transport and present on the cel-
l’s surface [11]. The H63D mutation seems to have a less
prominent biological impact, but acts synergistically
with the C282Y mutation [11]. The identification of
HFE as a gene responsible for hemochromatosis has
been confirmed through the development of an animal
model [13]. It is well known that T2DM and HH diag-
noses freqquently coexist [14,15]. Therefore, it would
seem a reasonable hypothesis that not only homozygous
carriers of HFE mutations, but also heterozygous carri-
ers as well, may be at higher risk of developing glucose
metabolic abnormalities. This theory is further support-
ed by the fact that subtle biochemical defects can often
be seen in the heterozygous state. For example, higher
serum ferritin levels and transferrin saturation have
been observed [16].
The studies performed thus far have not provided a
clear answer regarding a possible association of the HFE
gene with T2DM, and substantial differences have been
shown between ethnic groups [10]. Thus it is important
to determine the possible role of this gene in various
populations.
The aims of our study were:
1) To identify the frequency of C282Y and H63D muta-
tions in a population from the Ma∏opolska region of
south-eastern Poland, and
2) To search for an association between HFE mutations
and T2DM in this population.
MATERIAL AND METHODS
We included 391 unrelated individuals in this study:
222 T2DM patients and 169 non-diabetic controls. All
study participants were Caucasians and residents of the
Malopolska region of south-eastern Poland. WHO defi-
nitions and criteria were used during patient recruit-
ment [17]. Patients received a standard questionnaire
that contained questions regarding their age at T2DM
diagnosis, family history, treatment method, and other
medical issues. Only patients with a clinical diagnosis of
T2DM, age of onset later than 35 years, and no insulin
therapy for at least the two years immediately after
diagnosis were recruited. The control group consisted
of individuals with normal fasting glucose and a nega-
tive family history of T2DM among all first-degree rela-
tives. This group primarily constituted spouses of
T2DM patients and volunteers from the Department of
Metabolic Diseases. All participants underwent a basic
physical examination, which included the measurement
of height, weight, and blood pressure. The fasting glu-
cose level was determined by the enzymatic method.
HbA1c was measured in the T2DM patient group by the
HLPC method (Biorad). This study was performed in
compliance with the Helsinki Declaration and approved
by the Ethical Committee of the Jagiellonian Univer-
sity’s College of Medicine.
DNA from the examined individuals was isolated from
peripheral blood lymphocytes using GIBCO’s DNAzol
Reagent [18]. This DNA was then used to amplify the
HFE gene fragments containing the described variants.
We used the primer sequences published by Jazwinska
et al. for the C282Y mutation [19], with later modifica-
tion of the reverse primer sequence, as described by
Jeffrey et al, to assure specificity of genotyping [20].
Previously published primers were also used for the
H63D mutation [9]. The PCR products were digested
according to the supplier’s recommendation (Fermen-
tas) using specific restriction enzymes, SnaBI and
DpnII, to detect mutations at residues 282 and 63,
respectively. The C282Y mutation creates an SnaBI
restriction site, while the H63D mutation abolishes a site
for DpnII. Digestion products were separated on an
ethidium-bromide stained, 3% agarose gel. The results
were documented digitally and stored as computer files
using Biocapt software (Vilbert-Lourmant).
Statistical analysis
Differences in the distribution of alleles and genotypes
were assessed using the chi-squared test. Hardy-
Weinberg equilibrium was examined with the goodness-
of-fit chi-squared test. Comparisons between study
groups were made with Student’s t-test for quantitative
traits. Qualitative traits were analyzed using the chi-
squared test. For all statistical analyses, STATISTICA
for Windows was used (Statsoft Inc, Tulsa, Oklahoma,
USA).
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The amino acid variants of the HFE gene at residues 63
and 282 were determined in 391 individuals: 222
T2DM patients and 169 non-diabetic controls. Clinical
characteristics for both study groups can be found in
Table 1. The genotypes were in Hardy-Weinberg equi-
librium for both cases and controls. Details of allele and
genotype distributions are shown in Table 2. In general,
there was no difference between the two groups, but a
trend toward higher frequency of wild/H63D and
H63D/H63D genotypes was observed among T2DM
cases. There was one C282Y homozygote and one com-
pound heterozygote in each group. In addition to the
results shown in the Table 2, we performed two strati-
fied analyses. For this analysis, we divided our patient
group based on age of onset (<49 or ≥49 years, the
mean age of T2DM onset for the entire patient group)
and gender. In T2DM cases who developed disease
later in life (114 individuals), the frequency of the H63D
allele was 16.7%, while wild/H63D and H63D/H63D
genotypes constituted 32.4% in this subgroup. The
prevalence of the wild/H63D and H63D/H63D geno-
types among these T2DM patients was significantly dif-
ferent from controls (1 d.f., χ2=5.51; p=0.018).
Similarly, male patients (108 individuals) with T2DM
were characterized by a higher frequency of alleles and
genotypes with aspartate (18.1% and 35.2%, respective-
ly). These values were also significantly different from
the control group (1 df, χ2=5.11; p=0.023 and 1 df,
χ2=7.7; p=0.005 for alleles and genotypes, respective-
ly). Additionally, we looked at the clinical characteristics
of the H63D allele carriers at residue 63 of the HFE
gene. Overall, there were 61 hetero- or homozygous
carriers of this variant. On average, these patients were
50.9±9.0 years of age at diagnosis, while the remaining
members of the patient group developed T2DM at age
48.9±7.9 (p=0.12). There were significantly more men
in this group than among diabetic non-carriers of the
H63D allele (62.3% vs. 43.5%, p=0.012). BMI among
carriers was 30.3±4.6, very similar to members of the
non-carrier T2DM group (30.4±5.9). The allele and
genotype distributions observed in men and women
from the control group for H63D were similar. The
results from stratified analyses for the mutation at
residue 282 were not significant.
DISCUSSION
In this case-control study we searched for an association
of two mutations in the HFE gene with T2DM in a
homogenous, Caucasian population from the Ma∏opol-
ska region of south-eastern Poland.
The studies published to date have not provided an
unambiguous answer regarding the role of HFE muta-
tions in the pathogenesis of T2DM. Four studies per-
formed in different Cauciasian populations from
Germany, the UK, France, and New Zealand were not
able to show an association of either mutation with
T2DM [21–24]. However, three other studies suggested
that indeed this gene might influence susceptibility to
T2DM. For example, in one of these studies, involving a
Spanish population, it was observed that the H63D
allele’s frequency at residue 63 of the HFE gene was sig-
nificantly increased in T2DM patients [22]. In two other
Caucasian studies, the C282Y allele at residue 282 was
Sex (women/men )
Age at examination (years)*
Age at diagnosis (years)*
Duration of the disease (years)*
BMI (kg/m2)*
Fasting glucose (mmol/l)*
HbA1c (%)*
% on insulin treatment
% with positive family history of T2DM
in first degree relatives
The high proportion of insulin-treated type 2 diabetes patients was related
to the relatively long mean duration of diabetes. Fasting glucose was measured
in T2DM patients prior to administration of morning dose of antidiabetic
medications.
*Data are given as mean±SD; **N/A = not applicable
wt –wild type
114/108
59.8±8.9
49.1±7.7
10.7±6.9
30.3±5.6
9.2±9.0
7.8±1.8
55.0%
46.4%
95/74
55.1±14.7
N/A**
N/A
27.5±5.8
4.8±0.8
N/A**
N/A**
0.0%
Parameters ControlsT2DM
Table 1. Characteristics of the study groups.
Codon 63
T2DM patients
Controls
Codon 282
T2DM patients
Controls
wt
380 (85.6 %)
300 (88.8%)
wt
436 (98.2%)
327 (96.8%)
H63D
64 (14.4 %)
38 (11.2%)
C282Y
8 (1.8%)
11 (3.2%)
c2=1.7
1 .d.f
p=0.19
c2= 1.7
1.d.f
p=0.19
wt/wt
161 (72.5%)
135 (79.9%)
wt/wt
215 (96.8%)
159 (94.1%)
wt/H63D and
H63D/H63D
61 (27.5 %)
34 (20.1%)
wt/C282Y and
C282Y/C282Y
7 (3.2%)
10 (5.9%)
c2=2.8
1.d.f
p=0.09
c2= 1.7
1.d.f
p=0.18
Allele Genotype
Table 2. Allele and genotype distribution of the HFE gene in T2DM patients and controls.
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more prevalent in the T2DM patient groups [23,24].
Interestingly, one of these studies came from a Polish
population originating from the Silesia region [24].
Moczulski et al. have also suggested a possible role of
the H63D allele at residue 63 of the examined HFE
gene in T2DM susceptibility. This prompted us to test
this observation in a population from the neighboring
Ma∏opolska region. In the present study, we were not
able to confirm the previously reported role of the
C282Y mutation in the pathogenesis of T2DM in a
Polish population. In fact, we observed the opposite
trend, towards a higher frequency of this mutation in
controls than in T2DM cases. We did observe, however,
a tendency toward higher prevalence of the H63D allele
in the group of T2DM patients. Additionally, we per-
formed stratified analyses of the data, hypothesizing
that, since HH usually develops during the later stages
of adulthood [10,15], the effects of heterozygous muta-
tions may potentially be detectable in patients with late
onset T2DM. Stratification was further justified consid-
ering that, since iron loss is often associated with menses
and pregnancy, the clinical expression of HFE gene
variants would presumably be more severe in men than
in women [28]. Indeed, we found evidence supporting
the notion that the H63D mutation may constitute a
susceptibility allele for late onset forms of T2DM and in
males. While it has been shown that the H63D mutation
does not have such profound effects on the HFE pro-
tein’s function as the C282Y mutation, it does reduce
the HFE protein’s functional influence on the transfer-
rin receptor [11]. In addition, patients with T2DM who
were heterozygous for the H63D allele have been found
to exhibit some physiological abnormalities, such as
high plasma ferritin level [25]. Thus an iron overload
that leads to decreased β-cell secretion of insulin and to
insulin resistance [29,30] may be one of the mechanisms
of T2DM pathogenesis in these individuals. However,
there is a possibility that another, as yet unidentified
mechanism not associated with iron metabolism exists
through which the H63D mutation of the HFE gene
influences susceptibility to T2DM
Additionally, the difference in terms of the C282Y
mutation observed between two studies using Polish
ethnic population warrants further discussion. While
both projects used a case-control study design, a model
that is sensitive and optimal in the search for association
between a polymorphism and a complex disease [31],
the two studies produced different results in respect to
this mutation. While an association between T2DM and
the tyrosine variant at residue 282 was found in the
Silesia population, the opposite trend was observed in
the study group from the Malopolska region. One possi-
ble explanation for this discrepancy is that the results
from the Silesia study constitute a type 1 error. This
error could have occurred because of population strati-
fication [32,33]. It is well known that case-control analy-
ses may identify spurious associations if case and control
subjects are drawn differentially from two or more sub-
populations, when marker allele frequencies and disease
prevalence differ across these subpopulations. As the
population from the Silesia region experienced several
waves of migration, particularly in the 20th century, and
subsequently ethnic admixtures, this possibility cannot
be entirely excluded. It should also be emphasized that,
with an observed minor allele frequency of 1–2%, the
C282Y mutation represents a relatively poor marker for
examination in complex diseases, such as T2DM [33].
This mutation may also be prone to producing spurious
associations as a result of random variation. These types
of inconsistencies have been previously described, not
only between different races and nations, but also within
the same ethnic groups [7,34,35,36]. These differences
may have occurred not only due to population stratifica-
tion and random variation, as mentioned above, but
also as a result of power differences that are influenced
by the size of the study groups, as well as allele and dis-
ease frequency [33]. We postulate that to fully deter-
mine whether H63D and C282Y alleles are susceptibili-
ty variants for T2DM, additional studies in different
populations are required. It seems likely that, as was the
case for the PPARγ Pro12Ala variant, a large meta-
analysis could eventually help to further define the role
of the examined sequence differences [8].
CONCLUSIONS
The frequency of HH-associated mutations in a popula-
tion from the Ma∏opolska region of south-eastern
Poland is similar to that found in other Caucasian popu-
lations. We found no evidence supporting the recently
reported association of the C282Y mutation with T2DM
in this Polish population. The results of our study do,
however, suggest that the H63D mutation may play a
role in the pathogenesis of late onset T2DM and in
males in our population.
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